Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.This Tysabri (natalizumab) market report delivers an ...

A severe inflammatory reaction of the brain occurred in two natalizumab-treated MS patients after removal of the drug by plasmapheresis with or without immunoadsorption. Natalizumab, a monoclonal ...

If approved, the Tysabri (natalizumab) biosimilar – originally developed by Polpharma Biologics – will be sold by Novartis' Sandoz unit for all of the originator drug's indications in the two ...

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Tysabri (natalizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market ...